title: The protection of Rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin.
abstract: Rhein lysinate (RHL) is the salt of lysine and rhein and the objective of this study was to investigate the protection of RHL to liver in diabetic mice. The model of type 2 diabetes was established by high-fat diet and streptozotocin treatment. Malondialdehyde, superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were measured using a spectrophotometer. Inflammatory factors (TNF-α and IL-6) and related proteins (ERK1/2 and SREBP-1c) were analyzed by Western blot. Tissue profile was determined by hematoxylin and eosin staining and accumulation of fat was examined by Nile red staining. The results indicated that plasma glucose levels of type 2 diabetic mice were over 13.9 mM. Compared with model group, plasma glucose levels were decreased, however insulin levels were increased in RHL (25 and 50 mg/kg)-treated group. Elevated plasma triglyceride and cholesterol were also markedly attenuated after RHL treatment. The activities of SOD and GSH-Px of livers were increased after RHL treatment. Livers of RHL-treated mice had more normal structure and less steatosis than that of diabetic mice. Moreover, RHL decreased the expression of TNF-α and IL-6 and the phosphorylation of SREBP-1c and ERK1/2. In conclusion, RHL has a noticeable hepatic protection in diabetic mice.
authors: The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730, China.
authors: Ya-Jun
authors: YJ
authors: Lin
authors: Gang
authors: G
authors: Hu
authors: Kai-Ji
authors: KJ
authors: Li
authors: Yu-Fang
authors: YF
authors: Zhao
authors: Jie
authors: J
authors: Wei
authors: Yong-Zhan
authors: YZ
authors: Zhen
mesh_terms: D000818:Animals; D000880:Anthraquinones / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D059305:Diet, High-Fat / Q000009:adverse effects*; D005234:Fatty Liver / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017382:Reactive Oxygen Species / Q000378:metabolism; D013311:Streptozocin / Q000633:toxicity*
chemical_list: D000880:Anthraquinones; D001786:Blood Glucose; D017382:Reactive Oxygen Species; C583741:rhein lysinate; D013311:Streptozocin; D008239:Lysine